article thumbnail

Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData

Express Pharma

billion by 2029. “ Gilead’s Trodelvy (sacituzumab govetican), marketed for advanced breast and bladder cancer, is seeking a label expansion for first-line NSCLC in combination with Keytruda. billion in 2023, and GlobalData projects it to surpass $14 billion by 2029. GlobalData estimates the drug to earn $3.12

article thumbnail

BMS expands Krazati’s FDA label to include colorectal cancer

Pharmaceutical Technology

The KRAS inhibitor, Krazati, is expected to generate $1.3bn in global sales in 2029, as per GlobalData’s analysis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

J&J’s Akeega FDA approval to heat up PARP battle with dual-action treatment for prostate cancer:  GlobalData

Express Pharma

Akeega’s current predicted sales will experience only a slight increase as a result of its narrow label and fierce competition with other recently approved poly(ADP-ribose) polymerase (PARP) inhibitors, according to GlobalData. billion by 2029. However, the combination presents with potentially higher efficacy than Akeega.

article thumbnail

Intra-Cellular Therapies acquisition will expand J&J’s presence in neurology space, says GlobalData

Express Pharma

GlobalData forecasts that Caplyta could generate sales of $640 million in MDD by 2029 in the 7MM. Opdenakker continues, The addition of Caplyta could be particularly significant, given its versatility as a proven treatment for schizophrenia and bipolar disorder, as well as a potential label expansion into MDD.

Labelling 105
article thumbnail

Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit

pharmaphorum

The approval comes despite scrutiny of the safety of the JAK inhibitor class by the FDA, with the risk of heart-related issues leading to warnings being applied to the labels of Olumiant and other drugs in the class including Pfizer’s Xeljanz (tofacitinib) and AbbVie’s Rinvoq (upadacitinib).

article thumbnail

Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3

pharmaphorum

billion a 25% gain in the prior year and fuelled in part by extensions to its label to include other progressive ILDs. Ofev is, however, heading for patent expiry in 2029, and Boehringer is looking to BI 1015550 to maintain the franchise beyond that date, and also to improve the treatment of IPF, which remains incurable.

article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.